Table 2 Baseline features by genotype and treatment assignment (n = 170).
From: Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder
Genotype group | CC (N = 61; 35.9%) | AC/AA (N = 109; 64.1%) | P values | ||||
|---|---|---|---|---|---|---|---|
Medication group | Topiramate (N = 30) | Placebo (N = 31) | Topiramate (N = 55) | Placebo (N = 54) | Medication group | Genotype group | Interaction effect |
Demographics | |||||||
Sex (Male) | 22 (73%) | 24 (77%) | 39 (71%) | 36 (67%) | 0.86 | 0.35 | 0.56 |
Age (yr)a | 53.0 (11.9) | 47.9 (14.6) | 51.9 (9.8) | 51.2 (11.6) | 0.20 | 0.57 | 0.27 |
Marital statusb | 16 (53%) | 15 (48%) | 31 (56%) | 36 (67%) | 0.52 | 0.18 | 0.33 |
Employment status | 0.15 | 0.99 | 0.40 | ||||
Full-time | 20 (67%) | 20 (65%) | 31 (56%) | 38 (70%) | |||
Part-time | 2 (7%) | 6 (19%) | 11 (20%) | 10 (19%) | |||
Not Working | 8 (27%) | 5 (16%) | 13 (24%) | 6 (11%) | |||
Education (yr)a | 16.4 (2.3) | 15.6 (2.9) | 16.0 (2.4) | 16.7 (2.1) | 0.61 | 0.35 | 0.07 |
Annual income level | 0.27 | 0.80 | 0.59 | ||||
<$40,000 | 1 (3%) | 8 (26%) | 11 (20%) | 3 (6%) | |||
$40,000–$79,999 | 8 (27%) | 4 (13%) | 7 (13%) | 10 (19%) | |||
$80,000–$119,000 | 9 (30%) | 8 (26%) | 14 (25%) | 21 (39%) | |||
≥$120,000 | 12 (40%) | 11 (35%) | 23 (42%) | 20 (37%) | |||
Clinical measures | |||||||
Lifetime major depression | 7 (23%) | 11 (35%) | 11 (20%) | 8 (15%) | 0.87 | 0.08 | 0.21 |
Lifetime anxiety disorder | 5 (17%) | 6 (19%) | 4(7%) | 10 (19%) | 0.13 | 0.39 | 0.34 |
PHQ-9 scorea | 5.1 (3.4) | 6.1 (4.1) | 5.0 (4.2) | 5.4 (4.5) | 0.32 | 0.49 | 0.62 |
Drinking daysa,c | 86.6% (15.2) | 85.6% (17.0) | 87.5% (17.3) | 86.9% (16.9) | 0.71 | 0.71 | 0.98 |
Heavy drinking Daysa,c | 70.6% (22.8) | 65.5% (26.2) | 75.6% (23.9) | 68.7% (25.6) | 0.18 | 0.20 | 1.0 |
SIP scorea,c | 14.0 (7.9) | 15.2 (10.3) | 14.4 (9.1) | 13.8 (9.4) | 0.98 | 0.71 | 0.53 |
